Early intravenous immunoglobulin therapy for group A β-haemolytic streptococcal meningitis with toxic shock syndrome.
Derick K AdigbliValerie RozenArchie DarbarPierre JaninPublished in: BMJ case reports (2021)
A woman in her forties was transferred to a Sydney (Australia)-based tertiary hospital, following presentation to a regional hospital with group A Streptococcus (GAS) otomastoiditis; complicated by meningitis, venous sinus thrombosis, haemorrhagic cerebral infarction and subdural empyema. She rapidly deteriorated with profound cardiovascular collapse. Despite initiation of high dose vasoactive therapy, she remained shocked and developed multiorgan dysfunction syndrome. Early intravenous immunoglobulin therapy (140 g in two doses) was initiated as an adjunct to antimicrobial, surgical and supportive care for refractory streptococcal toxic shock syndrome. Over the course of a twelve-day intensive care unit stay she made good progress with de-escalation of her vasoactive supportive care and reversal of her organ injuries. She was subsequently discharged to ward-based care. At her three-month follow-up appointment she had significantly reduced neurological deficit. Five months following her presentation to hospital she had returned to full-time work.
Keyphrases
- high dose
- healthcare
- case report
- intensive care unit
- palliative care
- quality improvement
- low dose
- pain management
- staphylococcus aureus
- stem cell transplantation
- oxidative stress
- emergency department
- stem cells
- open label
- randomized controlled trial
- adverse drug
- mesenchymal stem cells
- blood brain barrier
- electronic health record
- cystic fibrosis